ClinicalTrials.gg
TerminatedNCT00689052Updated Jun 9, 2014Results posted

Pramipexole ER vs. Placebo in Fibromyalgia

A Phase 2 interventional study of pramipexole ER and placebo in Fibromyalgia, sponsored by Boehringer Ingelheim. Terminated at 42 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-09.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 369 studies in Fibromyalgia with a site in United States — 52 open to participants now, 63 under way, 2 of them phase 3. Fibromyalgia · United States.

Enrollment
173rd of 320
61 · median 72
Started
2008
with 16 others
Phase 2
44 of 369
2 open now
Registered
85th of 369
by date

Among the 369 studies in Fibromyalgia with a site in United States, this one is the 173rd largest by enrollment of the 320 interventional ones that give a count, is one of 17 that started in 2008, is one of 44 in phase 2, and was the 85th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

52 of the 369 studies in Fibromyalgia with a site in United States are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Fibromyalgia with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the efficacy and safety of an extended-release (ER) formulation of pramipexole in comparison with placebo for the treatment of fibromyalgia.

The objective of the open-label phase is to assess the safety profile and effect of Pramipexole (PPX) extended-release (ER) in fibromyalgia patients over a 24-week period.

03

Conditions studied

  • Fibromyalgia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female outpatients greater than or equal to 18 years of age
  2. Meet criteria for primary fibromyalgia as defined by the American College of Rheumatology (ACR): widespread aching pain in all four quadrants of the body and axial skeleton for greater than 3 months duration and greater than or equal to 11 of 18 tender points under digital palpitation examination with an approximate force of 4 kilograms per centimeters squared (kg/cm2)
  3. Pain score of greater than or equal to 4 (scored once at screening and as a weekly mean at baseline) on the 11-point Likert pain scale with 0 = no pain and 10 = worst possible pain
  4. Score of greater than or equal to 4 (= moderately ill) on the Clinical Global Impression of Severity (CGI-S) at screening and at baseline
  5. All females of must test negative for pregnancy at Visit 1. Females of child-bearing potential (not surgically sterilized and between menarche and two years ) must agree to utilize medically acceptable and reliable means of as determined by the investigator during the study and for one month following the last dose of study medication. Examples of reliable methods include: use of hormonal contraception (oral, injectable, or subcutaneous), double-barrier method, abstinence, partner with vasectomy, or hormonal intrauterine devices
  6. Educational level and degree of understanding such that the patient can communicate intelligibly with the investigator and study coordinator
  7. Judged to be reliable and agree to keep all appointments for clinic visits, tests, and procedures required by the protocol

Exclusion criteria

Exclusion Criteria:

  1. Employees of Boehringer Ingelheim (BI) (that is, employees, temporary contract workers, or designees responsible for the conduct of the study)
  2. Have received treatment within 30 days prior to screening with a drug that has not received regulatory approval for any indication
  3. Have previously completed or withdrawn from this study or any other study investigating pramipexole.
  4. Any current or previous diagnosis of psychosis, bipolar disorder, or schizoaffective disorder as assessed by the Mini International Neuropsychiatric Interview (MINI)
  5. Have any primary anxiety disorder within the past year as assessed by the Mini International Neuropsychiatric Interview (MINI)
  6. Have any Diagnosis of Statistical Manual of Mental Diseases, 4th Edition () Axis II disorder that would interfere with protocol compliance
  7. Medium or high risk of suicidality as assessed by the Mini International Neuropsychiatric Interview (MINI)
  8. History of substance abuse/dependence within the past year, excluding nicotine and caffeine
  9. A positive urine drug screen for any substance of abuse or excluded medication
  10. Women who are pregnant or breast-feeding
  11. Have pain symptoms related to traumatic injury that will interfere with the interpretation of outcome measures
  12. Patients with regional pain syndromes, multiple surgeries or failed back surgery syndrome
  13. A confirmed or previous diagnosis of rheumatoid arthritis, inflammatory arthritis, or infectious arthritis, or an disease
  14. Abnormal C-Reactive Protein, Anti-Nuclear Antibody (ANA), Rheumatoid factor, or Thyroid Stimulating Hormone (TSH)
  15. Any serious or unstable medical or psychiatric condition or abnormalities in labs at screening that would lead to hospitalization during the course of the study or otherwise compromise study participation
  16. Have uncontrolled seizures
  17. Taking any prohibited medications that cannot be discontinued at screening
  18. Patients who are treatment- or whose response may be compromised by disability compensation issues
  19. Patients with frequent or severe allergic reactions to multiple medications
  20. Prior or current treatment with pramipexole
  21. Clinically significant renal disease
  22. Current or previous diagnosis of malignant melanoma
  23. Clinically relevant ophthalmopathy
  24. Documented sleep apnea
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Pramipexole ER

    0.75 mg to 4.5 mg tablets of Pramipexole ER, once daily in the evening

    Drug: pramipexole ER

  • Placebo comparator
    Placebo

    Placebo tablets, once daily in the evening

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The Change in the Weekly Mean of the 24-hour Average Pain Score From a Daily Diary as Measured by the 11-point Likert Pain Scale

    The 11-point Likert Pain Scale is a numerical rating scale completed by the patient that measures the intensity of pain. The intensity scores range from 0 (no pain) to 10 (worst possible pain)

    Time frame: Baseline and Week 29

Secondary outcomes

  1. The Proportion of Patients "Very Much Improved" or "Much Improved" on the Patient's Global Impression of Improvement (PGI-I) 7-point Scale

    PGI-I is a self-reported scale completed by the patient that measures the degree of improvement at the time of assessment. The score ranges from 1 = very much improved to 7 = very much worse

    Time frame: Week 29 (at the end of the maintenance phase)

  2. The Short Form 36 (SF-36) Health Survey, Physical Functioning Subscale (Change From Baseline).

    The SF-36 Health Survey is a self-administered 36-item instrument completed by the patient . SF 36 has subscales as follows: i) physical functioning (PF), ii) role limitations due to physical problems (RP), iii) bodily pain (BP), iv) general health perceptions (GH), v) vitality (VT), vi) social function (SF), vii) role limitations due to emotional problems (RE), viii) mental health (MH),ix)physical component summary (PCS)and x)mental component summary(MCS). Among the subscales, Physical functioning was key secondary endpoint while other were additional secondary endpoints. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The number of items per domain varies from 2 to 1

    Time frame: Baseline and Week 29

  3. The Proportion of Patients With at Least a 30% or at Least a 50% Improvement Relative to Baseline in Pain (Assessed on the 11-point Likert Pain Scale

    11-Point Likert Pain Scale is a numerical rating scale completed by the patient that measures the intensity of pain. The intensity scores range from: 0 = no pain to 10 = worst possible pain .

    Time frame: Baseline and Week 29

  4. Fibromyalgia Impact Questionnaire (FIQ) Total Score (Change From Baseline)

    FIQ is a self-reported scale completed by the patient that measures patient status, progress, and outcomes over the past week. The FIQ is composed of a total of 20 items; the first 11 items measure physical functioning, and each item is rated on a four-point Likert scale. Items 12 and 13 measure the number of days the patient felt well and the number of days the patient felt unable to work due to their fibromyalgia symptoms. Items 14 through 20 are numerical, 11-point Likert scales (marked in 10-point increments) on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety, and depression. The total score ranges from 0 to 80. A higher score indicates a more negative impact

    Time frame: Baseline and Week 29

  5. Hospital Anxiety and Depression Scale (HADS) (Change From Baseline).

    The Hospital Anxiety and Depression Scale (HADS) measures the severity of anxiety and depression. The severity score ranges from: 0 = least severe to 3 = most severe. The total score ranges from 0 to 21; the higher the score, the more severe the anxious/depressive symptoms

    Time frame: Baseline and Week 29

  6. The Short Form 36 (SF-36) Health Survey (Change From Baseline) (Excluding the Physical Functioning Subscale(PF)).

    The SF-36 Health Survey is a self-administered 36-item instrument completed by the patient . SF 36 has subscales as follows: i) physical functioning (PF), ii) role limitations due to physical problems (RP), iii) bodily pain (BP), iv) general health perceptions (GH), v) vitality (VT), vi) social function (SF), vii) role limitations due to emotional problems (RE), viii) mental health (MH),ix)physical component summary (PCS)and x)mental component summary(MCS). Among the subscales, Physical functioning was key secondary endpoint while other were additional secondary endpoints. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The number of items per domain varies from 2 to 1

    Time frame: Baseline and Week 29

  7. Euroqol- 5 Dimensions (EQ-5D) Survey (Change From Baseline)

    The Euroqol- 5 Dimension (EQ-5D) Health Survey is a generic, multidimensional, health related, quality-of-life instrument that contains two parts-a health status profile and a visual analog scale (VAS) to rate global health-related quality of life. The profile contains five items corresponding to five health domains- mobility, self-care, usual activities, pain/discomfort, and mood. A single score is generated for each health state. Data from the EQ-5D can be converted into 243 unique health states. For each health state, there exists a corresponding valuation that allows the patient's health to be represented as an index, which is a value between -0.594 and 1; the higher the score, the better the quality of life.

    Time frame: Baseline and Week 29

  8. Multidimensional Assessment of Fatigue (MAF) Index (Change From Baseline)

    The Multidimensional Assessment of Fatigue (MAF) Index is a 16-item, self-reporting instrument designed to collect data on four dimensions of fatigue- severity, distress, degree of interference in activities of daily living, and timing .

    Time frame: Baseline and Week 29

  9. Medical Outcomes Study (MOS) Sleep Scale (Change From Baseline)

    The Medical Outcomes Study (MOS) sleep scale is a 12-item (MOS1 to MOS12) self reporting sleep measure.

    Time frame: Baseline and Week 29

  10. Clinical Global Impression of Severity (CGI-S Scores)

    Clinical Global Impression of Severity (CGI-S) Scale is a clinician's assessment of patient's severity of illness. The score ranges from 1 = normal, not at all ill to 7 = among the most extremely ill patients

    Time frame: Baseline and Week 29

  11. Frequency of Rescue Medication for Pain

    Acetaminophen/paracetamol (maximum of 4 g/day) to be allowed as rescue medication for pain.

    Time frame: Week 29

  12. Change From Baseline in Mean Tender Point Threshold

    The Tender Point Pain Threshold will be assessed for all 18 tender points by a study clinician. A dolorimeter will be used to exert the pressure at each point and to measure the threshold reading; when the patient first indicates pain, the threshold will be recorded in kg/sq.cm ;If the patient reports pain before 1.0 kg/sq.cm is reached (\>0 kg/sq.cm), 1.0 kg/sq.cm will be entered. If the patient does not report pain when the maximum pressure is applied (10.0 kg/sq.cm),0 (no pain) will be entered.

    Time frame: Baseline and Week 29

07

Results

Posted Nov 25, 2009
Limitations and caveats
Early termination leading to no number of subjects analysed for any outcome measure

Participant flow

Participant flow — Overall Study
MilestonePlaceboPramipexole
Started3130
Completed00
Not completed3130
Withdrew: Adverse event46
Withdrew: Protocol violation10
Withdrew: Lost to follow-up20
Withdrew: Withdrawal by subject20
Withdrew: Early termination of the trial2224

Outcome measures

PrimaryThe Change in the Weekly Mean of the 24-hour Average Pain Score From a Daily Diary as Measured by the 11-point Likert Pain Scale

The 11-point Likert Pain Scale is a numerical rating scale completed by the patient that measures the intensity of pain. The intensity scores range from 0 (no pain) to 10 (worst possible pain)

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

SecondaryThe Proportion of Patients "Very Much Improved" or "Much Improved" on the Patient's Global Impression of Improvement (PGI-I) 7-point Scale

PGI-I is a self-reported scale completed by the patient that measures the degree of improvement at the time of assessment. The score ranges from 1 = very much improved to 7 = very much worse

Time frame:
Week 29 (at the end of the maintenance phase)

No measurements were reported for this outcome.

SecondaryThe Short Form 36 (SF-36) Health Survey, Physical Functioning Subscale (Change From Baseline).

The SF-36 Health Survey is a self-administered 36-item instrument completed by the patient . SF 36 has subscales as follows: i) physical functioning (PF), ii) role limitations due to physical problems (RP), iii) bodily pain (BP), iv) general health perceptions (GH), v) vitality (VT), vi) social function (SF), vii) role limitations due to emotional problems (RE), viii) mental health (MH),ix)physical component summary (PCS)and x)mental component summary(MCS). Among the subscales, Physical functioning was key secondary endpoint while other were additional secondary endpoints. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The number of items per domain varies from 2 to 1

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

SecondaryThe Proportion of Patients With at Least a 30% or at Least a 50% Improvement Relative to Baseline in Pain (Assessed on the 11-point Likert Pain Scale

11-Point Likert Pain Scale is a numerical rating scale completed by the patient that measures the intensity of pain. The intensity scores range from: 0 = no pain to 10 = worst possible pain .

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

SecondaryFibromyalgia Impact Questionnaire (FIQ) Total Score (Change From Baseline)

FIQ is a self-reported scale completed by the patient that measures patient status, progress, and outcomes over the past week. The FIQ is composed of a total of 20 items; the first 11 items measure physical functioning, and each item is rated on a four-point Likert scale. Items 12 and 13 measure the number of days the patient felt well and the number of days the patient felt unable to work due to their fibromyalgia symptoms. Items 14 through 20 are numerical, 11-point Likert scales (marked in 10-point increments) on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety, and depression. The total score ranges from 0 to 80. A higher score indicates a more negative impact

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

SecondaryHospital Anxiety and Depression Scale (HADS) (Change From Baseline).

The Hospital Anxiety and Depression Scale (HADS) measures the severity of anxiety and depression. The severity score ranges from: 0 = least severe to 3 = most severe. The total score ranges from 0 to 21; the higher the score, the more severe the anxious/depressive symptoms

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

SecondaryThe Short Form 36 (SF-36) Health Survey (Change From Baseline) (Excluding the Physical Functioning Subscale(PF)).

The SF-36 Health Survey is a self-administered 36-item instrument completed by the patient . SF 36 has subscales as follows: i) physical functioning (PF), ii) role limitations due to physical problems (RP), iii) bodily pain (BP), iv) general health perceptions (GH), v) vitality (VT), vi) social function (SF), vii) role limitations due to emotional problems (RE), viii) mental health (MH),ix)physical component summary (PCS)and x)mental component summary(MCS). Among the subscales, Physical functioning was key secondary endpoint while other were additional secondary endpoints. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The number of items per domain varies from 2 to 1

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

SecondaryEuroqol- 5 Dimensions (EQ-5D) Survey (Change From Baseline)

The Euroqol- 5 Dimension (EQ-5D) Health Survey is a generic, multidimensional, health related, quality-of-life instrument that contains two parts-a health status profile and a visual analog scale (VAS) to rate global health-related quality of life. The profile contains five items corresponding to five health domains- mobility, self-care, usual activities, pain/discomfort, and mood. A single score is generated for each health state. Data from the EQ-5D can be converted into 243 unique health states. For each health state, there exists a corresponding valuation that allows the patient's health to be represented as an index, which is a value between -0.594 and 1; the higher the score, the better the quality of life.

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

SecondaryMultidimensional Assessment of Fatigue (MAF) Index (Change From Baseline)

The Multidimensional Assessment of Fatigue (MAF) Index is a 16-item, self-reporting instrument designed to collect data on four dimensions of fatigue- severity, distress, degree of interference in activities of daily living, and timing .

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

SecondaryMedical Outcomes Study (MOS) Sleep Scale (Change From Baseline)

The Medical Outcomes Study (MOS) sleep scale is a 12-item (MOS1 to MOS12) self reporting sleep measure.

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

SecondaryClinical Global Impression of Severity (CGI-S Scores)

Clinical Global Impression of Severity (CGI-S) Scale is a clinician's assessment of patient's severity of illness. The score ranges from 1 = normal, not at all ill to 7 = among the most extremely ill patients

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

SecondaryFrequency of Rescue Medication for Pain

Acetaminophen/paracetamol (maximum of 4 g/day) to be allowed as rescue medication for pain.

Time frame:
Week 29

No measurements were reported for this outcome.

SecondaryChange From Baseline in Mean Tender Point Threshold

The Tender Point Pain Threshold will be assessed for all 18 tender points by a study clinician. A dolorimeter will be used to exert the pressure at each point and to measure the threshold reading; when the patient first indicates pain, the threshold will be recorded in kg/sq.cm ;If the patient reports pain before 1.0 kg/sq.cm is reached (\>0 kg/sq.cm), 1.0 kg/sq.cm will be entered. If the patient does not report pain when the maximum pressure is applied (10.0 kg/sq.cm),0 (no pain) will be entered.

Time frame:
Baseline and Week 29

No measurements were reported for this outcome.

Adverse events

Collected over Up to 72 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/31 (3.2%)10/31 (32.3%)
Pramipexole—0/30 (0%)18/30 (60%)
Most frequent serious events
Most frequent serious events
EventPlaceboPramipexole
Iron deficiency anaemiaBlood and lymphatic system disorders1/310/30
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboPramipexole
nauseaGastrointestinal disorders3/317/30
insomniaPsychiatric disorders3/315/30
somnolenceNervous system disorders1/315/30
fatigueGeneral disorders0/314/30
sleep attacksPsychiatric disorders0/313/30
dry mouthGastrointestinal disorders0/313/30
arthralgiaMusculoskeletal and connective tissue disorders3/311/30
dizzinessNervous system disorders1/312/30
headacheNervous system disorders2/312/30
Gastrooesophageal diseaseGastrointestinal disorders0/312/30

Baseline characteristics

Treated Set, All patients randomized and received treatment

Age, Continuous
Age, Continuous(years)PlaceboPramipexoleTotal
Mean52.3 ± 10.350.7 ± 9.751.5 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPramipexoleTotal
Female303060
Male101
08

Study locations

42 sites
  • 248.637.01009 Boehringer Ingelheim Investigational Site
    Birmingham, Alabama, United States
  • 248.637.01033 Boehringer Ingelheim Investigational Site
    Phoenix, Arizona, United States
  • 248.637.01045 Boehringer Ingelheim Investigational Site
    Tucson, Arizona, United States
  • 248.637.01034 Boehringer Ingelheim Investigational Site
    Hot Springs, Arkansas, United States
  • 248.637.01032 Boehringer Ingelheim Investigational Site
    Arcadia, California, United States
  • 248.637.01044 Boehringer Ingelheim Investigational Site
    Los Angeles, California, United States
  • 248.637.01036 Boehringer Ingelheim Investigational Site
    Santa Ana, California, United States
  • 248.637.01042 Boehringer Ingelheim Investigational Site
    Englewood, Colorado, United States
  • 248.637.01031 Boehringer Ingelheim Investigational Site
    Danbury, Connecticut, United States
  • 248.637.01035 Boehringer Ingelheim Investigational Site
    Deland, Florida, United States
  • 248.637.01023 Boehringer Ingelheim Investigational Site
    Ft. Myers, Florida, United States
  • 248.637.01047 Boehringer Ingelheim Investigational Site
    Orlando, Florida, United States
  • 248.637.01043 Boehringer Ingelheim Investigational Site
    Palm Beach Gardens, Florida, United States
  • 248.637.01040 Boehringer Ingelheim Investigational Site
    Sunrise, Florida, United States
  • 248.637.01027 Boehringer Ingelheim Investigational Site
    Tampa, Florida, United States
  • 248.637.01007 Boehringer Ingelheim Investigational Site
    Atlanta, Georgia, United States
  • 248.637.01028 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 248.637.01010 Boehringer Ingelheim Investigational Site
    Lexington, Kentucky, United States
  • 248.637.01016 Boehringer Ingelheim Investigational Site
    Newton, Massachusetts, United States
  • 248.637.01014 Boehringer Ingelheim Investigational Site
    Lansing, Michigan, United States
  • 248.637.01020 Boehringer Ingelheim Investigational Site
    Flowood, Mississippi, United States
  • 248.637.01018 Boehringer Ingelheim Investigational Site
    Picayune, Mississippi, United States
  • 248.637.01012 Boehringer Ingelheim Investigational Site
    Kansas City, Missouri, United States
  • 248.637.01017 Boehringer Ingelheim Investigational Site
    Billings, Montana, United States
  • 248.637.01024 Boehringer Ingelheim Investigational Site
    Albuquerque, New Mexico, United States
  • 248.637.01008 Boehringer Ingelheim Investigational Site
    Albany, New York, United States
  • 248.637.01002 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 248.637.01025 Boehringer Ingelheim Investigational Site
    Charlotte, North Carolina, United States
  • 248.637.01026 Boehringer Ingelheim Investigational Site
    Fargo, North Dakota, United States
  • 248.637.01004 Boehringer Ingelheim Investigational Site
    Cincinnati, Ohio, United States
  • 248.637.01038 Boehringer Ingelheim Investigational Site
    Columbus, Ohio, United States
  • 248.637.01003 Boehringer Ingelheim Investigational Site
    Oklahoma City, Oklahoma, United States
  • 248.637.01046 Boehringer Ingelheim Investigational Site
    Medford, Oregon, United States
  • 248.637.01006 Boehringer Ingelheim Investigational Site
    Portland, Oregon, United States
  • 248.637.01039 Boehringer Ingelheim Investigational Site
    Duncansville, Pennsylvania, United States
  • 248.637.01015 Boehringer Ingelheim Investigational Site
    Warwick, Rhode Island, United States
  • 248.637.01019 Boehringer Ingelheim Investigational Site
    Austin, Texas, United States
  • 248.637.01037 Boehringer Ingelheim Investigational Site
    San Antonio, Texas, United States
  • 248.637.01041 Boehringer Ingelheim Investigational Site
    Salt Lake City, Utah, United States
  • 248.637.01021 Boehringer Ingelheim Investigational Site
    Renton, Washington, United States
  • 248.637.01029 Boehringer Ingelheim Investigational Site
    Seattle, Washington, United States
  • 248.637.01011 Boehringer Ingelheim Investigational Site
    Spokane, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008 and a primary completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2008
First posted
Jun 3, 2008
Start
Jul 2008
Primary completionActual
Nov 2008
Results first posted
Nov 25, 2009
Last update
Jun 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00689052
Responsible party
Sponsor
First posted
Jun 3, 2008
Start date
Jul 2008
Primary completion
Nov 2008
Results posted
Nov 25, 2009
Last update
Jun 9, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion